TargetBeta
TNFRSF13C
TNF receptor superfamily member 13C · also BAFFR, CD268 · CD molecules
3 programs in company-led studies act on TNFRSF13C, from 3 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ianalumab | Novartis | phase 3 | 3416 running | – | the company's pipeline |
| Anti-BAFFR Monoclonal Antibody ESG206rule | Shanghai Escugen Biotechnology | phase 2 | 53 running | – | NCIt |
| Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199rule | Eli Lilly | phase 1 | 11 running | CD3E | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Lupus Erythematosus, Systemic, 2 programs
- Purpura, Thrombocytopenic, Idiopathic, 2 programs
- Arthritis, Rheumatoid, 1 program
- Lupus Nephritis, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Sjogren's Syndrome, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 26, 2027ianalumab · Novartis · phase 3 · NCT05639114
- Apr 2027Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199 · Eli Lilly · phase 1 · NCT07101328
- Dec 31, 2027Anti-BAFFR Monoclonal Antibody ESG206 · Shanghai Escugen Biotechnology · phase 2 · NCT07375524
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.